参考文献
1.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Malignant Pleural Mesothelioma Version 1.2019 — February 7, 2019.
2.American Joint Committee on Cancer(AJCC)Cancer Staging System(8th ed., 2017).
3.Linton A, Pavlakis N, O’Connell R, et al.Factors associated with survival in a large series ofpatients with malignant pleural mesothelioma in New South Wales.Br J Cancer 2014, 111: 1860-1869.
4.Taioli E, Wolf AS, Camacho-Rivera M, et al.Determinants of survival in malignant pleural mesothelioma: a Surveillance, Epidemiology, and EndResults(SEER)studyof14, 228patients.PLoS One 2015, 10: e0145039.
5.Chang ET, Lau EC, Mowat FS, et al.Therapeutic radiation for lymphoma and risk of second primary malignant mesothelioma.Cancer Causes Control 2017, 28: 971-979.
6.Li X, Brownlee NA, Sporn TA, et al.Malignant(diffuse)mesothelioma in patients with hematologic malignancies: aclinicopathologicstudyof45cases.Arch Pathol Lab Med 2015,139: 1129-1136.
7.Betti M, Casalone E, Ferrante D, et al.Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma.Cancer Lett 2017, 405: 38-45.
8.Ohar JA, Cheung M, Talarchek J, et al.Germline BAP1 mutational landscape of asbestos-exposed malignant mesothelioma patients with familyhistory of cancer.Cancer Res 2016, 76: 206-215.
9.Kindler HL, Ismaila N, Armato SG, et al.Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.J Clin Oncol 2018, JCO2017766394.
10.Johnen G, Gawrych K, Raiko I, et al.Calretinin as a blood-based biomarker for mesothelioma.BMC Cancer 2017, 17: 386.
11.Armato SG, Coolen J, Nowak AK, et al.Imaging in pleural mesothelioma: A review of the 12th International Conference of the International Mesothelioma Interest Group.Lung Cancer 2015, 90: 148-154.(https://www.daowen.com)
12.Panou V, Vyberg M, Weinreich UM, et al.The established and future biomarkers ofmalignant pleural mesothelioma.Cancer Treat Rev 2015, 41: 486-495.
13.Husain AN, Colby TV, Ordonez NG, et al.Guidelines for pathologic diagnosis ofmalignant mesothelioma: 2017 update of the consensus statement from the International Mesothelioma Interest Group.Arch Pathol Lab Med 2018, 142: 89-108.
14.Marchevsky AM, LeStang N, Hiroshima K, etal.The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic(sarcomatoid)carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.Hum Pathol 2017, 67: 160-168.
15.Arif Q, Husain AN.Malignant mesothelioma diagnosis.Arch Pathol Lab Med 2015, 139: 978-980.
16.Taioli E, van Gerwen M, Mihalopoulos M, et al.Review of malignant pleural mesothelioma survival after talc pleurodesis or surgery.J Thorac Dis 2017, 9: 5423-5433.
17.Cao C, Tian D, Park J, et al.A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.Lung Cancer 2014, 83: 240-245.
18.Spaggiari L, Marulli G, Bovolato P, et al.Extrapleural pneumonectomy for malignant mesothelioma: an Italian multicenter retrospective study.Ann Thorac Surg 2014, 97: 1859-1865.
19.Blomberg C, Nilsson J, Holgersson G, et al.Randomized trials of systemic medically-treated malignant mesothelioma: a systematic review.Anticancer Res 2015, 35: 2493-2501.
20.Kim JS, Lim SY, Hwang J, etal.Acasereportof primary pericardial malignant mesothelioma treated with pemetrexed and cisplatin.J Korean Med Sci 2017, 32: 1879-1884.
21.Kapeles M, Gensheimer MF, Mart DA, et al.Trimodality treatment of malignant pleural mesothelioma: an institutional review.Am J Clin Oncol 2018, 41: 30-35.